|Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Organization Market (CMO), Forecast to 2024|
|Advancements in Continuous Manufacturing Technology, Necessary to Meet New Demand in the Orphan Drugs Segment and Personalized Medicine, Will Give a New Growth Vector to CMOs|
Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners instead of contractors. Sponsors are looking for partnerships to not only append their existing capacity and get access to new markets, but also to mitigate risk and bring overhaul in manufacturing technologies. Consequently, safety, efficacy, and product quality are outweighing cost-saving considerations..